DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Centro Nacional de Investigaciones Oncológicas
Madrid, EspañaPublications en collaboration avec des chercheurs de Centro Nacional de Investigaciones Oncológicas (18)
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features
Frontiers in Oncology, Vol. 13
2022
-
BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up
European Urology
-
Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
Therapeutic Advances in Medical Oncology, Vol. 14
-
Cabozantinib for the treatment of solid tumors: a systematic review
Therapeutic Advances in Medical Oncology, Vol. 14
-
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis
OncoImmunology, Vol. 11, Núm. 1
-
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
Cancers, Vol. 14, Núm. 12
-
Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy
Journal of Clinical Medicine, Vol. 11, Núm. 3
2021
2020
-
Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy
Cancers, Vol. 12, Núm. 7, pp. 1-13
2019
-
CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status
Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402
2018
-
A genetic polymorphism in ctla-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma
Clinical Cancer Research, Vol. 24, Núm. 10, pp. 2350-2356
2017
-
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity
Urologic Oncology: Seminars and Original Investigations, Vol. 35, Núm. 8, pp. 529.e9-529.e16
-
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma
Pharmacogenetics and Genomics, Vol. 27, Núm. 6, pp. 227-231
-
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
Oncotarget, Vol. 8, Núm. 1, pp. 1204-1212
2015
-
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
European Journal of Clinical Pharmacology, Vol. 71, Núm. 12, pp. 1477-1484
-
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors
Molecular Carcinogenesis, Vol. 54, Núm. 7, pp. 566-576
-
Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993